Mednax Net Worth
Mednax Net Worth Breakdown | MD |
Mednax Net Worth Analysis
Mednax's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mednax's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mednax's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mednax's net worth analysis. One common approach is to calculate Mednax's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mednax's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mednax's net worth. This approach calculates the present value of Mednax's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mednax's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mednax's net worth. This involves comparing Mednax's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mednax's net worth relative to its peers.
Enterprise Value |
|
To determine if Mednax is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mednax's net worth research are outlined below:
| Mednax Inc appears to be risky and price may revert if volatility continues | |
| The company generated the yearly revenue of 1.99 B. Annual Net Loss to common stockholders was (60.41 M) with gross profit of 467.03 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Pediatrix Medical Group Downgraded by StockNews.com to Hold |
Mednax Quarterly Good Will |
|
Mednax uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mednax Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mednax's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 16th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 16th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Mednax's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mednax is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mednax Inc backward and forwards among themselves. Mednax's institutional investor refers to the entity that pools money to purchase Mednax's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-06-30 | 1.4 M | Segall Bryant & Hamill | 2024-09-30 | 1.2 M | Caspian Capital Partners, L.p. | 2024-09-30 | 1.1 M | Citadel Advisors Llc | 2024-09-30 | 1.1 M | Jpmorgan Chase & Co | 2024-06-30 | 1 M | Aqr Capital Management Llc | 2024-06-30 | 942.4 K | Dana Investment Advisors Inc | 2024-09-30 | 915.6 K | Weiss Asset Management Lp | 2024-09-30 | 912.8 K | Bank Of America Corp | 2024-06-30 | 899.9 K | Blackrock Inc | 2024-06-30 | 13.7 M | Vanguard Group Inc | 2024-09-30 | 10.7 M |
Follow Mednax's market capitalization trends
The company currently falls under 'Mid-Cap' category with a market capitalization of 1.28 B.Market Cap |
|
Project Mednax's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.07) | (0.07) |
When accessing Mednax's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mednax's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mednax's profitability and make more informed investment decisions.
Please note, the presentation of Mednax's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mednax's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mednax's management manipulating its earnings.
Evaluate Mednax's management efficiency
Mednax Inc has Return on Asset (ROA) of 0.0467 % which means that for every $100 of assets, it generated a profit of $0.0467. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.2986) %, which implies that it produced no returns to current stockholders. Mednax's management efficiency ratios could be used to measure how well Mednax manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.07. In addition to that, Return On Capital Employed is expected to decline to 0. At present, Mednax's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 86.3 M, whereas Other Assets are forecasted to decline to about 212.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.11 | 9.67 | |
| Tangible Book Value Per Share | (6.62) | (6.95) | |
| Enterprise Value Over EBITDA | 47.17 | 49.53 | |
| Price Book Value Ratio | 0.92 | 0.87 | |
| Enterprise Value Multiple | 47.17 | 49.53 | |
| Price Fair Value | 0.92 | 0.87 | |
| Enterprise Value | 1.3 B | 1.2 B |
Management at Mednax Inc focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.8709 | Revenue 2 B | Quarterly Revenue Growth 0.009 | Revenue Per Share 24.174 | Return On Equity (0.30) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mednax insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mednax's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mednax insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mednax Corporate Filings
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 1st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 31st of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Mednax Earnings per Share Projection vs Actual
Mednax Corporate Directors
| Enrique Sosa | Independent Director | Profile | |
| Paul Gabos | Independent Director | Profile | |
| Pascal Goldschmidt | Independent Director | Profile | |
| Waldemar Carlo | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.11) | Earnings Share (2.34) | Revenue Per Share 24.174 | Quarterly Revenue Growth 0.009 | Return On Assets 0.0467 |
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.